MAB3
LIVE

Serial Number

79381287

Owner

F-star Therapeutics Limited

Attorney

Shoko Naruo

Filing Date

Sep 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MAB3 Trademark

Serial Number: 79381287 • Registration: 7683035

MAB3 is a trademark filed by F-star Therapeutics Limited on September 14, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

F-star Therapeutics Limited (3 trademarks)

Eddeva B920,

Entity Type: 99

INVOX PHARMA LIMITED

Suite 2, First Floor, The Westworks,

Entity Type: 99

Trademark Details

Filing Date

September 14, 2023

Registration Date

February 11, 2025

Published for Opposition

December 24, 2024

Goods & Services

Scientific and technological services, namely, scientific research and design in the field of monoclonal antibodies for medical purposes; scientific research, namely, industrial analysis and research services in the field of monoclonal antibodies for medical purposes; pharmaceutical, medical, scientific and biopharmaceutical research and development in the field of monoclonal antibodies for medical purposes; drug discovery services; research relating to medicines; research and development of medicines; development of pharmaceutical and biopharmaceutical preparations and medicines

Biological preparations for scientific, industrial, and research use; immunoglobulins being monoclonal antibodies, monoclonal antibodies, and fragments thereof, for scientific, industrial, and research use

Pharmaceutical, biopharmaceutical and medical preparations, agents and substances, namely, preparations, agents and substances all containing or being monoclonal antibodies for medical purposes for treatment of cancer, oncological diseases and disorders, infectious diseases and disorders, inflammation and diseases, disorders and conditions associated with inflammation, inflammatory diseases and disorders, and neurological diseases and disorders; immunoglobulins being monoclonal antibodies, monoclonal antibodies, and fragments thereof, for medical use; products in the nature of pharmaceutical preparations and medicines containing immunoglobulins being monoclonal antibodies, monoclonal antibodies, and fragments thereof, for use in medicine

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 19, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 28, 2025 FICS
FINAL DISPOSITION PROCESSED
Aug 28, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 11, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 4, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 18, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 18, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 11, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 24, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 24, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 18, 2024 NONP
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Nov 28, 2024 ERRR
CHANGE OF OWNER RECEIVED FROM IB
Nov 22, 2024 CHLD
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 21, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 21, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 21, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 20, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Nov 20, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 20, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 20, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 20, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 20, 2024 COAR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 20, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 20, 2024 TROA
REFUSAL PROCESSED BY IB
Jun 17, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 24, 2024 RFCS
REFUSAL PROCESSED BY MPU
May 24, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 15, 2024 RFCR
NON-FINAL ACTION WRITTEN
May 14, 2024 CNRT
ASSIGNED TO EXAMINER
May 8, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 31, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 25, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 19, 2023 REPR